News | October 14, 2008

Cardiogenesis Hosts TCT Symposium on Cardiac Regenerative Medicine

October 15, 2008 - Cardiogenesis Corp. sponsored an educational symposium entitled "New Horizons in Cardiac Regenerative Medicine: Advancements in Revascularization & Stem Cell Therapy," this week in conjunction with the TCT meeting in Washington, D.C.

The symposium was attended by over 120 cardiology healthcare practitioners and chaired by Warren Sherman, M.D., director of Cardiac Cell Based Endovascular Therapies, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center. Presenters included: Emerson Perin, M.D., Ph.D, director, New Interventional Cardiovascular Technology, Texas Heart Institute; Marvin Slepian, M.D., director of Interventional Cardiology, University of Arizona, Sarver Heart Center; and Keith Allen, cardiothoracic surgeon, Mid America Heart and Thoracic Surgeons, Kansas City, MO.

"The program was designed to provide an update to clinicians on the recent developments with advanced cardiovascular revascularization and regenerative therapies, with a focus on patients suffering from ischemic cardiac disease," Dr. Sherman stated. "TCT attendees are eager to learn about rapidly evolving therapies, as well as the latest information on optimizing outcomes with available tools and techniques, including TMR [transmyocardial revascularization] as a sole therapy and adjunctive to bypass surgery."

"Surgeons are innovating with Cardiogenesis to provide TMR with minimally invasive approaches, including surgical robotic delivery,” said Dr. Allen. He also discussed the early clinical experience with the PHOENIX combination delivery system being collected from centers outside the U.S.

As a leading clinical investigator of autologous stem cell trials, Dr. Perin provided a state-of-the-art overview of cardiovascular stem cell clinical trials. "The tissue-stimulated zone generated by TMR, along with the precise delivery of stem cells, may prove to be more potent in combination than either therapy alone," he explained.

For more information: www.cardiogenesis.com


Related Content

News | Stem Cell Therapies

November 19, 2021 — Stem cell therapy helped to reduce the number of heart attacks, strokes and death among people with ...

Home November 19, 2021
Home
News | Stem Cell Therapies

October 28, 2021 – The first patient has been treated in a new trial using stem cell therapy to treat chronic myocardial ...

Home October 28, 2021
Home
Videos | Stem Cell Therapies

Mechanical engineering Professor Nathan Sniadecki, associate chair for research and infrastructure, mechanical ...

Home October 04, 2021
Home
Feature | Stem Cell Therapies | By Simon H. Stertzer, M.D.

Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections ...

Home May 11, 2021
Home
Feature | Stem Cell Therapies | By Andy Freeberg

The University of Washington (UW) in Seattle has developed engineered heart tissue that beats. Though minuscule, the ...

Home February 25, 2021
Home
News | Stem Cell Therapies

August 22, 2019 — Renovacor Inc, a preclinical-stage biopharmaceutical company, announced the successful completion of ...

Home August 22, 2019
Home
News | Stem Cell Therapies

May 20, 2019 – Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from ...

Home May 20, 2019
Home
News | Stem Cell Therapies

April 19, 2019 — Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal ...

Home April 19, 2019
Home
News | Stem Cell Therapies

March 4, 2019 — The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding ...

Home March 04, 2019
Home
News | Stem Cell Therapies

February 1, 2019 — A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts ...

Home February 01, 2019
Home
Subscribe Now